Bristol Myers to buy RayzeBio for $4.1B as pharma piles into burgeoning radiopharma field
Bristol Myers Squibb plans to buy radiopharmaceuticals biotech RayzeBio for about $4.1 billion, it announced Tuesday, hot on the heels of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
